U.S. biotech firm Horizon Therapeutics was among the top global performers last week, with its stock soaring nearly 21% for the week.
It raised its full-year 2022 net sales guidance to a range of between $3.59 billion and $3.61 billion.
Analysts covering the stock are positive on its future performance, with nearly 87% giving it a "buy" rating and price target upside of 36%, according to FactSet.
The stock bucked the trend of a decline in global stocks last week, with the MSCI World Index dipping around 2% for the week.
Still, seven global stocks, including Horizon, soared more than 20%.